Estrogen receptor: Difference between revisions

(5 intermediate revisions by 2 users not shown)

Line 1:

{{ Infobox immunostain

| Name = {{PAGENAME}}

| Image = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg

| Width =

| Caption = ER+ve in metastatic breast carcinoma.

| Abbrev = ER

| Synonyms =

| Similar =

| Clones =

| Use =

| Subspecial =

| Pattern = nuclear staining

| Positive = Breast and endometrial carcinoma

| Negative =

| Other =

}}

'''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]].

Line 7:

Line 24:

==Positive==

*Normal breast - usually patchy staining.

*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining.<ref name=Ref_BP276>{{Ref BP|276}}</ref>

*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.

*[[Breast carcinoma]] - most.

**[[Ductal carcinoma in situ]] - most, usually diffuse.<ref name=Ref_BP276>{{Ref BP|276}}</ref>

**[[Ductal carcinoma in situ]] - most, usually diffuse<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.

**[[Invasive lobular carcinoma]] - all.

**[[Invasive ductal carcinoma of the breast]] - most.

*[[Endometrial carcinoma]]s.

* PRL-producing [[pituitary adenoma]]s (Prolactioma)<ref>{{Cite journal | last1 = Delgrange | first1 = E. | last2 = Vasiljevic | first2 = A. | last3 = Wierinckx | first3 = A. | last4 = François | first4 = P. | last5 = Jouanneau | first5 = E. | last6 = Raverot | first6 = G. | last7 = Trouillas | first7 = J. | title = Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. | journal = Eur J Endocrinol | volume = 172 | issue = 6 | pages = 791-801 | month = Jun | year = 2015 | doi = 10.1530/EJE-14-0990 | PMID = 25792376 }}</ref>

===Occasionally positive===

Line 22:

Line 41:

==See also==

*[[Breast pathology]].

*[[Tamoxifen]].

==References==

@@ Line 1: / Line 1: @@
+{{ Infobox immunostain
+| Name       = {{PAGENAME}}
+| Image      = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg
+| Width      =
+| Caption    = ER+ve in metastatic breast carcinoma.
+| Abbrev     = ER
+| Synonyms   =
+| Similar    =
+| Clones     =
+| Use        =
+| Subspecial =
+| Pattern    = nuclear staining
+| Positive   = Breast and endometrial carcinoma
+| Negative   =
+| Other      =
+}}
 '''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]].
@@ Line 7: / Line 24: @@
 ==Positive==
 *Normal breast - usually patchy staining.
-*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining.<ref name=Ref_BP276>{{Ref BP|276}}</ref>
+*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.
 *[[Breast carcinoma]] - most.
-**[[Ductal carcinoma in situ]] - most, usually diffuse.<ref name=Ref_BP276>{{Ref BP|276}}</ref>
+**[[Ductal carcinoma in situ]] - most, usually diffuse<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.
 **[[Invasive lobular carcinoma]] - all.
 **[[Invasive ductal carcinoma of the breast]] - most.
 *[[Endometrial carcinoma]]s.
+* PRL-producing [[pituitary adenoma]]s (Prolactioma)<ref>{{Cite journal  | last1 = Delgrange | first1 = E. | last2 = Vasiljevic | first2 = A. | last3 = Wierinckx | first3 = A. | last4 = François | first4 = P. | last5 = Jouanneau | first5 = E. | last6 = Raverot | first6 = G. | last7 = Trouillas | first7 = J. | title = Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. | journal = Eur J Endocrinol | volume = 172 | issue = 6 | pages = 791-801 | month = Jun | year = 2015 | doi = 10.1530/EJE-14-0990 | PMID = 25792376 }}</ref>
 ===Occasionally positive===
@@ Line 22: / Line 41: @@
 ==See also==
 *[[Breast pathology]].
+*[[Tamoxifen]].
 ==References==

Estrogen receptor: Difference between revisions

Navigation menu

Search